August 18, 2015

Chrysalis BioTherapeutics’ TP508 Reverses Radiation-Induced GI Damage

GALVESTON, Texas, Aug. 18, 2015 /PRNewswire/ — Chrysalis BioTherapeutics, Inc. today announced publication of data demonstrating that TP508, the company’s lead drug candidate, activates stem cells in the gastrointestinal (GI) system to prevent breakdown of the intestinal mucosa and decrease ionizing radiation-induced mortality.  The studies, published online at Nature Journals (Laboratory Investigation,  http://www.nature.com/doifinder/10.1038/labinvest.2015.103), showed that a single

Read More »